Payment overview · 2025
General Payments
$1,175.03
48 reported records · 17 companies
Healthcare provider profile · identity verified
Douglas Michael Pennington, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1891714580
Verified facts
What the public records show
CMS Open Payments records show Douglas Michael Pennington, D.O. received $1,175.03 in general payments during 2025 across 48 reported records.
GlaxoSmithKline, LLC. accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $169.59 | 14.4% | 8 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $149.02 | 12.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.38 | 10.0% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $99.80 | 8.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.85 | 7.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.63 | 7.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.78 | 6.6% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.83 | 4.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.70 | 4.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.55 | 4.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.89 | 4.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.40 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.88 | 3.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.25 | 3.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.29 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.24 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.95 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,175.03 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $145.35 | 7 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $99.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.50 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $82.63 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.63 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $65.28 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.52 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $60.21 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.70 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.55 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.88 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 148 |
| Lisinopril | Lisinopril | 341 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 317 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 79 |
| Trazodone Hcl | Trazodone Hcl | 255 | 78 |
| Omeprazole | Omeprazole | 245 | 78 |
| Losartan Potassium | Losartan Potassium | 241 | 71 |
| Alprazolam | Alprazolam | 234 | 35 |
| Sertraline Hcl | Sertraline Hcl | 220 | 55 |
| Gabapentin | Gabapentin | 200 | 56 |
| Ibuprofen | Ibuprofen | 191 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 57 |
| Furosemide | Furosemide | 158 | 51 |
| Metformin Hcl Er | Metformin Hcl | 158 | 51 |
| Metformin Hcl | Metformin Hcl | 155 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 37 |
| Simvastatin | Simvastatin | 139 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 40 |
| Potassium Chloride | Potassium Chloride | 122 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 32 |
| Montelukast Sodium | Montelukast Sodium | 114 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 31 |
| Tramadol Hcl | Tramadol Hcl | 101 | 30 |
| Allopurinol | Allopurinol | 94 | 32 |
| Celecoxib | Celecoxib | 94 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 68 |
| Ozempic | Semaglutide | 93 | 21 |
| Jardiance | Empagliflozin | 92 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 83 | 30 |
| Pregabalin | Pregabalin | 80 | 14 |
| Carvedilol | Carvedilol | 78 | 28 |
| Azithromycin | Azithromycin | 76 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 25 |
| Clonazepam | Clonazepam | 71 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 20 |
| Meloxicam | Meloxicam | 64 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 63 | 18 |
| Nifedipine Er | Nifedipine | 59 | 18 |
| Estradiol | Estradiol | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 20 |
| Alendronate Sodium | Alendronate Sodium | 55 | 20 |
| Ondansetron Odt | Ondansetron | 55 | 22 |
| Glimepiride | Glimepiride | 53 | 16 |
| Promethazine Hcl | Promethazine Hcl | 51 | suppressed |
| Diazepam | Diazepam | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 49 | 41 |
| Mounjaro | Tirzepatide | 49 | 11 |
| Atenolol | Atenolol | 48 | 17 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 14 |
| Meclizine Hcl | Meclizine Hcl | 47 | 19 |
| Nystatin | Nystatin | 46 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 35 |
| Eliquis | Apixaban | 44 | 16 |
| Famotidine | Famotidine | 44 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 26 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 12 |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 12 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Valsartan | Valsartan | 26 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | 11 |
| Finasteride | Finasteride | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Naproxen | Naproxen | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,175.03 · 48 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BEXSERO, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, ROTARIX, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, UBRELVY, Veozah, XIFAXAN | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error